Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 182 resultados
LastUpdate Última actualización 17/11/2026 [08:29:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 50 a 75 de 182 nextPage  

GLUCAGON PATCH PUMP

NºPublicación:  EP4830625A1 28/10/2026
Solicitante: 
WILLOW LABORATORIES INC [US]
Willow Laboratories, Inc.
EP_4830625_PA

Resumen de: EP4830625A1

0001 A glucagon patch pump designed for managing glucose levels in individuals, particularly those with diabetes. The glucagon patch pump includes a base that attaches to a patient's tissue site, a medication bladder for storing glucagon, a medication pump with a conduit for delivering the medication, and a cannula insertion device that deploys the cannula when glucose levels fall below a predetermined threshold. The system can automatically administer glucagon in response to low glucose levels, reducing the need for second-party intervention and minimizing the risk of prolonged hypoglycemia. The glucagon patch pump can be part of a comprehensive glucose management system that includes a glucose sensor and a processor to monitor and respond to glucose levels.

GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY

NºPublicación:  EP4829026A1 28/10/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.
WO_2025137203_A1

Resumen de: WO2025137203A1

The present invention relates generally to systems, devices, and methods for in vivo monitoring of an analyte level. In particular, the present invention relates to sensors having saccharides or similar molecules present in glucose-oxidase containing sensing layers to improve sensor stability.

METHODS, DEVICES AND SYSTEM FOR PROVIDING DIABETIC CONDITION DIAGNOSIS AND THERAPY

NºPublicación:  US20260325017A1 22/10/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.
US_20260325017_A1

Resumen de: US20260325017A1

0000 Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.

INFUSION DEVICES AND RELATED MEAL BOLUS ADJUSTMENT METHODS

NºPublicación:  US20260325752A1 22/10/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc.
US_20260325752_A1

Resumen de: US20260325752A1

0000 Techniques disclosed herein relate to infusion devices and related meal bolus adjustment methods. In some embodiments, the techniques may involve determining an initial bolus amount to compensate for food consumption. The techniques may further involve predicting an initial value for a physiological condition based at least in part on the initial bolus amount and one or more insulin deliveries. The techniques may further involve identifying an adjusted bolus amount based on the predicted value. The techniques may further involve causing delivery of the adjusted bolus amount.

Methods and compositions for treating hepatocellular carcinoma using antisense

NºPublicación:  AU2026242160A1 22/10/2026
Solicitante: 
THOMAS JEFFERSON UNIV
Thomas Jefferson University
AU_2026242160_A1

Resumen de: AU2026242160A1

The present disclosure relates to compositions and methods for treating liver cancers, especially hepatocellular carcinoma, using antisense (AS) nucleic acids directed against Insulin- like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of liver cancer. ep e p

LENS-TYPE MEDICAL DETECTION DEVICE

NºPublicación:  US20260325083A1 22/10/2026
Solicitante: 
CHEN CHI HSIU [TW]
CHEN CHI-HSIU
US_20260325083_A1

Resumen de: US20260325083A1

A lens-type medical detection device includes a SoC connected to a display, a communication module, a remote measurement module, and a fall detection module. The communication module establishes connection with a cloud server and a contact person. The cloud server includes an artificial intelligence model. A light-emitting unit illuminates a subject and a lens successively captures multiple images, each of which is transmitted to the cloud server to be subjected to computation performed by the artificial intelligence model to generate physiological information, which is transmitted back and outputted to the display. The physiological information includes heartbeat, heart rate, blood pressure, blood oxygen, blood sugar, and lactic acid. Based on the physiological information, the artificial intelligence model generates a comprehensive health assessment for prompting proper handling to the subject and the family. The fall detection module detects a fall of the subject and notifies a contact person through the communication module.

METHOD FOR PROMOTING DIFFERENTIATION OF FIRST CELL INTO SECOND CELL, AND METHOD FOR IDENTIFYING TREATMENT THAT PROMOTES SAID DIFFERENTIATION

NºPublicación:  WO2026221010A1 22/10/2026
Solicitante: 
LOGOMIX INC [JP]
\u682A\u5F0F\u4F1A\u793E\uFF2C\uFF4F\uFF47\uFF4F\uFF4D\uFF49\uFF58
WO_2026221010_A1

Resumen de: WO2026221010A1

The present disclosure provides a method for identifying a treatment that promotes differentiation of a first cell into a second cell. The present disclosure also provides pancreatic beta cells or cells that are capable of differentiating into pancreatic beta cells. In the present disclosure, the pancreatic beta cells or cells that are capable of differentiating into pancreatic beta cells have a deletion of a specific gene, whereby the same preferably exhibit a high capability of differentiating into pancreatic beta cells, or exhibit a capability of differentiating into pancreatic beta cells exhibiting a glucose-dependent C-peptide secretion ability.

USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLS

NºPublicación:  US20260325585A1 22/10/2026
Solicitante: 
THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORATE [US]
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
US_20260325585_A1

Resumen de: US20260325585A1

Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.

USE OF A VARIABILITY METRIC OF GLUCOSE LEVEL VALUES TO IDENTIFY A SLEEPING TIME FRAME FOR A USER OF A MEDICAMENT DELIVERY DEVICE

NºPublicación:  AU2025249757A1 22/10/2026
Solicitante: 
INSULET CORP
INSULET CORPORATION
AU_2025249757_PA

Resumen de: AU2025249757A1

A variability metric of glucose level values of a user is calculated for each candidate sleeping time frame in a data set of glucose level values of the user obtained over time for a specified period for each day of multiple days. Each of the candidate sleeping time frames may represent a duration in which the user may have been sleeping. Execution of the programming instructions further may cause the processor to determine a mean or median of the variability metric of the glucose level values in the data set for each candidate sleeping time frame across the days in the specified period, designate a selected one of the candidate sleeping time frames that has the lowest mean or median variability metric as the sleeping time frame, and configure the pump to deliver a sleeping basal rate of the medicament for the designated sleeping time frame.

CYTIDINE DIPHOSPHOCHOLINE GLYCOSIDE, COMPOSITION, METHOD FOR PRODUCING GLYCOSIDE OF CYTIDINE RESIDUE-CONTAINING COMPOUND, GENE RECOMBINANT MICROORGANISM, METHOD FOR PRODUCING CYTIDINE RESIDUE-CONTAINING COMPOUND, AND METHOD FOR SUPPRESSING PRODUCTION OF GLYCOSIDE OF CYTIDINE RESIDUE-CONTAINING COMPOUND

NºPublicación:  AU2025255066A1 22/10/2026
Solicitante: 
KYOWA HAKKO BIO CO LTD
KYOWA HAKKO BIO CO., LTD.
AU_2025255066_PA

Resumen de: AU2025255066A1

The present invention relates to a cytidine diphosphocholine glycoside represented by general formula (1), a salt thereof, an N-oxide thereof, a solvate thereof, or the like. (In formula (1), R is a sugar residue.)

TECHNIQUES FOR EVALUATING IMPACTS BETWEEN PHYSIOLOGICAL DATA AND METABOLIC HEALTH

NºPublicación:  AU2025254093A1 22/10/2026
Solicitante: 
OURA HEALTH OY
OURA HEALTH OY
AU_2025254093_PA

Resumen de: AU2025254093A1

Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.

NONINVASIVE CONTINUOUS GLUCOSE MONITORING USING BANDPASS RAMAN SPECTROSCOPY

NºPublicación:  US20260325015A1 22/10/2026
Solicitante: 
MASSACHUSETTS INST OF TECHNOLOGY [US]
APOLLON INC [KR]
Massachusetts Institute of Technology
Apollon Inc.
US_20260325015_A1

Resumen de: US20260325015A1

0000 A method for noninvasive continuous glucose monitoring (CGM) using bandpass Raman spectroscopy (BRS) includes: irradiating, by a light source, light to a subject; detecting, by a photodetector, the light that is reflected from the subject; obtaining intensities of peaks at one or more predetermined Raman bands in a Raman spectrum occurring due to Raman shift, wherein the one or more predetermined Raman bands include a glucose Raman peak and two sidebands; and obtaining at least one glucose metric based on the intensities of peaks at the one or more predetermined Raman bands. The glucose metric is an area metric and/or a slope metric. Based thereon, a glucose level associated with the subject is determined.

SYSTEM FOR BLOOD GLUCOSE MANAGEMENT USING CONTINUOUS GLUCOSE MONITOR AND METHOD THEREOF

NºPublicación:  US20260325016A1 22/10/2026
Solicitante: 
ODN CO LTD [KR]
ODN Co., Ltd.
US_20260325016_A1

Resumen de: US20260325016A1

0000 Provided are a blood glucose management system using a continuous glucose monitor and a method therefor. The blood glucose management system may include a data collector configured to collect blood glucose data measured through a continuous glucose monitor worn by a patient; a data analyzer configured to analyze the collected blood glucose data to calculate values of a plurality of blood glucose variables representing a blood glucose state of the patient; and a data provider configured to provide the values of the blood glucose variables through a monitoring board. By using the system, the blood glucose states of patients can be thoroughly monitored and managed.

Recommendations based on continuous glucose monitoring

NºPublicación:  AU2026242121A1 22/10/2026
Solicitante: 
DEXCOM INC
Dexcom, Inc.
AU_2026242121_A1

Resumen de: AU2026242121A1

Recommendations based on continuous glucose monitoring (CGM) are described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform processes these measurements and the additional data to predict a health indicator by using models. This prediction serves as a basis for generating a recommendation, such as a message recommending the user take action or adopt a behavior to mitigate a predicted negative health condition. ep e p

SECURE WIRELESS COMMUNICATIONS BETWEEN A GLUCOSE MONITOR AND OTHER DEVICES

NºPublicación:  US20260325753A1 22/10/2026
Solicitante: 
INSULET CORP [US]
INSULET CORPORATION
US_20260325753_A1

Resumen de: US20260325753A1

0000 The exemplary embodiments may provide a secure framework for devices in a drug delivery system to wirelessly communicate. The secure framework may use encrypted keys to carry credentials and to specify the rights of the devices presenting the credentials. The devices in the drug delivery system present the keys at the time that they wish to wirelessly communicate with other devices in the drug delivery system. The devices receiving such keys, decrypt the keys and verify if the credentials are valid. If the credentials are valid, a wireless communication session between devices may be established.

METHOD AND APPARATUS FOR ELECTRICAL CURRENT THERAPY OF BIOLOGICAL TISSUE AND INSULIN RELEASE THEREFROM

NºPublicación:  US20260325852A1 22/10/2026
Solicitante: 
ROCKY MOUNTAIN BIPHASIC INC [US]
ROCKY MOUNTAIN BIPHASIC, INC.
US_20260325852_A1

Resumen de: US20260325852A1

The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal/cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.

CELL CULTURE PRODUCT AND USE THEREOF

NºPublicación:  US20260327567A1 22/10/2026
Solicitante: 
GUANGXIU GAOXIN LIFE SCIENCES CO LTD HUNAN [CN]
GUANGXIU-GAOXIN LIFE SCIENCES CO., LTD. HUNAN
US_20260327567_A1

Resumen de: US20260327567A1

0000 Provided are a cell culture product and the use thereof. The cell culture product comprises a hepatic progenitor cell proliferation medium, containing a DMEM/F12 medium, insulin, transferrin, sodium selenite, nicotinamide, 2-phosphate-L-ascorbic acid, a human recombinant albumin, an epidermal cell growth factor, a glycogen synthase kinase 3 inhibitor, a transforming growth factor β receptor inhibitor, lysophosphatidic acid, and sphingosine phosphate.

THERAPEUTIC AGENT FOR RENAL DISEASE AND RENAL FUNCTION-IMPROVING AGENT

NºPublicación:  US20260325582A1 22/10/2026
Solicitante: 
ROHTO PHARMACEUTICAL CO LTD [JP]
ROHTO PHARMACEUTICAL CO., LTD.
US_20260325582_A1

Resumen de: US20260325582A1

0000 The purpose of the present invention is to provide a novel therapeutic agent for renal disease. The present invention is a therapeutic agent for renal disease containing a mesenchymal stem cell culture supernatant. The mesenchymal stem cell culture supernatant is preferably a culture supernatant obtained from the cultivation of mesenchymal stem cells derived from adipose tissue, umbilical tissue, or bone marrow tissue. In addition, the mesenchymal stem cell culture supernatant is preferably obtained from the cultivation of mesenchymal stem cells in a culture medium containing at least one substance selected from the group consisting of EGF, bFGF, albumin, transferrin, and insulin.

SYSTEM AND METHOD FOR WIRELESS TRANSMISSION OF GLUCOSE DATA

NºPublicación:  EP4823433A1 21/10/2026
Solicitante: 
LAXMI THERAPEUTIC DEVICES INC [US]
Laxmi Therapeutic Devices, Inc.
KR_20260134356_PA

Resumen de: WO2025128082A1

A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.

HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATES

NºPublicación:  ME04900B 20/10/2026
Solicitante: 
AMICUS THERAPEUTICS INC [US]
Amicus Therapeutics, Inc.
AU_2015325028_A1

Resumen de: AU2015325028A1

Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.

GLP-1/GLP-2 BISPECIFIC POLYPEPTIDE AND USE THEREOF

NºPublicación:  WO2026214700A1 15/10/2026
Solicitante: 
BEIJING ZHIYUDAO BIOTECHNOLOGY CO LTD [CN]
\u5317\u4EAC\u667A\u4E8E\u9053\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
WO_2026214700_A1

Resumen de: WO2026214700A1

Provided in the present invention are a GLP-1/GLP-2 bispecific polypeptide and a fusion protein in which said polypeptide is fused to human IgG4-Fc. The GLP-1/GLP-2 bispecific polypeptide provided by the present invention can simultaneously activate GLP-1 and GLP-2 receptors, has a blood sugar control capability close to that of semaglutide, has a significant trophic effect on the small-intestine equivalent to that of teduglutide, and can markedly improve pathological features in mice with ulcerative colitis (UC).

AMNION-DERIVED CELL SECRETOME COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES

NºPublicación:  WO2026217569A1 15/10/2026
Solicitante: 
NOVEOME BIOTHERAPEUTICS INC [US]
NOVEOME BIOTHERAPEUTICS, INC
WO_2026217569_A1

Resumen de: WO2026217569A1

Methods and compositions for treating Alzheimer's disease and related neurodegenerative conditions using intranasal nose-to-brain delivery of ST266, an amnion-derived cell secretome are described. ST266 is a multi-component, acellular biologic composition produced from amnion-derived multipotent progenitor (AMP) cells under cGMP conditions and comprising a plurality of anti-inflammatory, neuroprotective, anti-apoptotic, and regenerative cytokines and growth factors. When administered intranasally, ST266 bypasses the blood-brain barrier and simultaneously targets multiple pathological mechanisms underlying Alzheimer's disease, including neuroinflammation, insulin dysregulation, oxidative stress, neuronal damage, and synaptic dysfunction. The invention encompasses pharmaceutical compositions formulated for intranasal nose-to-brain delivery, methods of treating Alzheimer's disease by administering such compositions, and methods of reducing neuroinflammation and improving insulin regulation in the central nervous system. The non-invasive nature of intranasal delivery offers significant advantages in patient compliance and minimization of systemic side effects.

SYSTEMS AND METHODS FOR AN AUTOREGRESSIVE SCHEME FOR SYNTHETIC TIME-SERIES GENERATION UNDER DATA SCARCITY

NºPublicación:  US20260315009A1 15/10/2026
Solicitante: 
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIV [US]
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
US_20260315009_A1

Resumen de: US20260315009A1

An autoregressive framework for synthetic data generation using an autoregressive generative model as an alternative to Generative Adversarial Networks (GAN). The autoregressive framework is applied to continuous glucose monitor data uses small real datasets to generate synthetic glycemic responses. The framework performs better than other systems because it works well with data constrained environments and can also evaluate contextual values in addition to past values.

PHARMACEUTICAL FORMULATIONS

NºPublicación:  AU2026242095A1 15/10/2026
Solicitante: 
NOVO NORDISK AS
Novo Nordisk A/S
AU_2026242095_A1

Resumen de: AU2026242095A1

Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes 5 and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein. ep e p

SYSTEMS AND METHODS FOR INCORPORATING CO-FORMULATIONS OF INSULIN IN AN AUTOMATIC INSULIN DELIVERY SYSTEM

Nº publicación: US20260315694A1 15/10/2026

Solicitante:

INSULET CORP [US]
INSULET CORPORATION

US_20260315694_A1

Resumen de: US20260315694A1

0000 Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

traducir